Search Results

Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Atypical Structure

About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Structure-based

Committee Sponsors GPCR Retreat Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure Recently, his team has applied cryo-EM to elucidation of the structure and dynamics of GPCRs. Prof.

optimize the design and engineering of more efficacious therapeutics. perspective in the pursuit of receptor subtype-specific ligands, a major aspect to achieve safer, on-target therapeutics The Sunahara lab has also been developing protein-based therapeutics using structure-guided design and A notable therapeutic is an enzyme that hydrolyzes cocaine. as a treatment for cocaine abuse, a debilitating disease that would require long-term and sustained therapeutic

New cryo-EM structures of GPR4 and GPR68 reveal how extracellular histidines act as proton sensors-trigger ➡️https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/structural-basis-and-biased-signaling-of-proton-sensation-by-gpcrs-mediated-by-extracellular-histidine-rearrangement New cryo-EM structures of GPR4 and GPR68 reveal how extracellular histidines act as proton sensors-trigger ➡️ https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function/structural-basis-and-biased-signaling-of-proton-sensation-by-gpcrs-mediated-by-extracellular-histidine-rearrangement

His main research group centers on the function, structure, and regulation of G protein-coupled receptors Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics

Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Kobilka’s lab contributing to the elucidation of high-resolution structures of various GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr.

An expert in GPCR biology, Fiona published the first description of the cloning and structural requirements As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery company, Fiona and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based

Her work involves the pharmacological and structural characterisation of novel putative antipsychotic molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

How target depletion and replenishment kinetics define the therapeutic window. How persistent binding alters structured tissue penetration — and why that matters for tumor targeting

field of pharmacology and biochemistry of GPCR and the crucial role of the lipidic environment on their structure In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

When persistent binding meets structured tissues, this effect can amplify or collapse. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure.

Activation and Signaling March 15th, 2024 GPCRs in Immunology and Oncology November 17, 2023 GPCRs as Therapeutic Modalities September 22, 2023 Structural and Molecular Insights into GPCR Activation July 21, 2023 GPCR

The Tiberi Lab pursues the study of the molecular, structural, pharmacological and signaling features We hope our research will aid in the development of new therapeutic interventions for the alleviation

embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic reflects the diverse fields of study encompassing GPCR research, such as biochemistry, pharmacology, structural

GPCR University Empowering Scientists to Advance GPCR Biology & Therapeutics 📚 Learn faster. 🤝 Connect players in GPCR pharmacology and learn how agonists and antagonists shape efficacy, signaling, and therapeutic orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Papers are critical, but DrGPCR offers structured training, expert analysis, and interaction with scientists Take the Next Step You're building the future of GPCR therapeutics.

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential signaling and drug discovery Symposium & Workshop - Brazil NEW April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities: Transforming receptor pharmacology - UK Biologist - Confo Therapeutics Associate Director/Director, Platform & Hit-ID Chemistry Lead - Septerna Pharmacologist - Schrödinger Scientist - Biology - Superluminal Medicines Scientist I Cell Biology - Tectonic Therapeutic

Neuroscience GPCRs in Oncology and Immunology Methods & Updates in GPCR Research Reviews, GPCRs, and more Structural : A New Prognostic Biomarker in Sarcoma Read More Methods & Updates in GPCR Research April 18, 2025 Structural Systems Biology Toolkit (SSBtoolkit): From Molecular Structure to Subcellular Signaling Pathways Read Biased signalling of Class B G protein-coupled receptor-targeted therapeutics Read More April 1, 2025 and molecular insights into GPCR function April 17, 2025 Structural dynamics of olfactory receptors:

Nicola J Smith is an expert in molecular pharmacology with a track record in exploring GPCR structure-function orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

He earned his Ph.D. at the Massachusetts Institute of Technology, where he studied MHC class II structure-function record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics discovery, he later co-founded Superluminal Medicines, a company using machine learning to explore GPCR structure-function

Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and

Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin, “Development of GPCR Ligands as Therapeutic Drugs” is coming up 🧐 Be the first to register ✳️Go to https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

“Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs “Development of GPCR Ligands as Therapeutic Drugs” with Dr. Terry Kenakin is here! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs

Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr.

lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic When persistent binding meets structured tissues, this effect can amplify or collapse. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. How target depletion and replenishment kinetics define the therapeutic window. “private” binding determinants ♦️ Highlights role of structured + unstructured regions ♦️ Includes a

students, and industry professionals eager to deepen their knowledge of GPCR signaling, pharmacology, and therapeutic re introducing foundational concepts or diving into advanced methodologies, our platform provides a structured Outline the structure : determine the number of modules and estimated duration (check the 'Course formats While this is not a real-time booking tool, it serves as a guideline to help structure our course lineup Terry Kenakin Development of GPCR Ligands and Therapeutic Drugs Up March 20 – April 10 4 weeks x 1 hour

During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

protein, senses cholesterol to regulate metabolism and cell growth ➡️https://www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function protein, senses cholesterol to regulate metabolism and cell growth ➡️ https:// www.ecosystem.drgpcr.com/structural-and-molecular-insights-into-gpcr-function